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Abstract: Background: Lung cancer (LC) is a major leading cause of death worldwide.
Immunomodulators that target several immune mechanisms have proven to reduce tumor burden
in experimental models through induction of the immune microenvironment. We hypothesized
that other biological mechanisms may also favor tumor burden reduction in lung cancer-bearing
mice treated with immunomodulators. Methods: Tumor weight, area, T cells and tumor growth
(immunohistochemistry), oxidative stress, apoptosis, autophagy, and signaling (NF-κB and sirtuin-1)
markers were analyzed (immunoblotting) in subcutaneous tumor of BALB/c mice injected with
LP07 adenocarcinoma cells treated with monoclonal antibodies (CD-137, CTLA-4, PD-1, and CD-19,
N = 9/group) and non-treated control animals. Results: Compared to non-treated cancer mice, in
tumors of monoclonal-treated animals, tumor area and weight and ki-67 were significantly reduced,
while T cell counts, oxidative stress, apoptosis, autophagy, activated p65, and sirtuin-1 markers were
increased. Conclusions: Immunomodulators elicited a reduction in tumor burden (reduced tumor
size and weight) through decreased tumor proliferation and increased oxidative stress, apoptosis,
autophagy, and signaling markers, which may have interfered with the immune profile of the tumor
microenvironment. Future research should be devoted to the elucidation of the specific contribution
of each biological mechanism to the reduced tumor burden.
Keywords: experimental lung cancer; immunomodulators; oxidative stress; autophagy; tumor
growth; sirtuin-1
1. Introduction
Lung cancer is the most prevalent cancer worldwide that affects both sexes and has a very high
mortality [1]. Despite the development of new therapeutic strategies, patients with lung cancer have
an overall survival rate lower than 15% in five years [1–3]. Respiratory conditions such as chronic
obstructive pulmonary disease (COPD) and lung fibrosis predispose patients to a greater risk to
develop lung cancer, especially non-small cell lung cancer (NSCLC) type [1,2,4–6].
The underlying biology of lung cancer is complex, as several mechanisms may interplay at different
stages. For instance, inflammation, which is key in host protection, may promote lung cancer initiation
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and malignancy in chronic inflammatory processes such as in patients with COPD [2,5,7–11]. Moreover,
oxidative stress was also shown to participate in tumor initiation, promotion, and progression of
carcinogenesis in patients with lung cancer, particularly in those with COPD [2,9,12,13]. Besides,
inflammatory events and oxidative stress may drive the release of a cascade of cytokines and growth
factors, which may favor lung tumorigenesis [2,9,12,13] through interference with biological processes
such as apoptosis and autophagy [11,13–15]. In the last few years, the implications of biological
mechanisms such as increased oxidative stress, inflammatory events, particularly a Th1-predominant
response, and epigenetic events were demonstrated to be differentially expressed in the lung tumors of
patients with COPD compared to patients without this respiratory condition [8,11,13,16]. These results
are important, since they may help establish a differential profile of patients that may be more or less
susceptible to certain therapies.
The immune system defends the host against diseases, including neoplastic transformation.
However, cancer cells may evade the host immune system through a process defined as cancer
immunoediting [17]. Cancer immune scape results from the action of immunosuppressive pathways
that involve membrane receptors that are located in immune cell types along different steps of the
cancer-immunity cycle [17–21]. Immune checkpoints enable immune tolerance to prevent autoimmunity
events in the host [17–22]. Several immune checkpoints have been identified so far. As such,
programmed cell death protein 1 (PD1) is a membrane receptor that promotes immune tolerance
through T cell inactivation [18,19,22]. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is a
disruptor of antigen presentation upon T cell activation [17]. Cluster of differentiation 137 (CD137) is
located in several immune cells such as T regulatory cells (Treg) that are responsible for repressing T
cell activity [21]. Additionally, B cells present cluster of differentiation 19 (CD19), which can trigger
pro- and anti-tumorigenic responses (Table 1) [20].
Table 1. Monoclonal antibodies for the treatment of lung tumors in mice.
Monoclonal Antibodies Targets Function
Anti-PD-1 PD-1 PD-1 receptor is expressed in activated T cells and inducesimmune tolerance by repressing T cell effector function [23,24].
Anti-CTLA-4 CTLA-4 CTLA-4 receptor is expressed in T cells and induces immunetolerance by repressing antigen presentation [23,25].
Anti-CD19 CD-19 CD-19 activates B cells [23,26].
Anti-CD137 CD-137 CD-137 receptor activates CD8+ T and NK cells [21,23].
Definition of abbreviations: PD-1, programmed cell death-1; CTLA-4, cytotoxic T-lymphocyte
associated protein-4; CD-137, TNF receptor superfamily member 9; CD-19; B-lymphocyte antigen;
NK, natural killer.Specific immune checkpoint inhibitors have been designed, namely monoclonal
antibodies that specifically act against these membrane receptors in order to boost the immune
microenvironment. The blockade of these inhibitory pathways has been shown to restore the anti-tumor
activity of the immune system [17,22,27–32]. The therapeutic efficacy of the combination of different
immunomodulatory monoclonal antibodies has been recently demonstrated in animal models of lung
cancer, in which the tumor immune microenvironment was specifically explored [18,19]. Furthermore,
in previous studies from our group [8,11–13,16,33], the contribution of inflammation and signaling
pathways [e.g., nuclear factor (NF)-kB and Sirtuin-1], oxidative stress, autophagy, and apoptosis in
response to several pharmacological strategies was shown in mice bearing lung tumors. Oxidative
stress was also shown to mediate the response to immunotherapy in colorectal cancer in mice [34] and
the chemoresistance in ovarian cancer of patients [35]. Whether similar biological mechanisms can be
observed in the tumors of mice treated with a combination of several immunomodulators remains to
be identified. Thus, we reasoned that immunomodulators may also exert beneficial effects on tumor
burden through biological events other than the immune microenvironment.
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On this basis, we hypothesized that treatment of a combination of specific immunomodulatory
monoclonal antibodies that included anti-PD1, anti-CTLA-4, anti-CD137, and anti-CD19 may have an
effect on tumor progression through several biological mechanisms such as oxidative stress, autophagy,
and apoptosis through specific signaling pathways in wild-type lung adenocarcinoma cells of mice [33].
Accordingly, in the current investigation, the main objectives were two-fold: (1) to assess the immune
tumor microenvironment (T cells) and (2) to quantify levels of oxidative stress, antioxidant enzymes,
apoptosis, autophagy, signaling, and cell proliferation rates in the subcutaneous lung adenocarcinoma
tumors of BALB/c mice treated with a combination of immunomodulators (anti-PD1, anti-CTLA-4,
anti-CD137, and anti-CD19 monoclonal antibodies). A group of tumor-bearing mice that did not
receive treatment with the cocktail of monoclonal antibodies was the control group in the study. This




The study protocol is illustrated in Figure 1. An animal model with lung cancer was developed
through the inoculation of cancer cells from LP07 stable adenocarcinoma cell line derived from P07 lung
tumor that spontaneously appeared in BALB/c mice [39–41]. Eighteen female BALB/c mice (8 weeks old,
20 g weight) acquired from Harlan Interfauna Ibérica SL (Barcelona, Spain) received a subcutaneous
inoculation of LP07 cells (4 × 105) resuspended in 0.2 mL of minimal essential medium (MEM) in the left
flank (Figure 1). After tumor cell inoculation on day 0 of all the mice, they were randomly divided into
two independent groups (N = 9/group) to be thereafter followed for 30 days: (1) experimental control
group in which mice received an intraperitoneal administration of 0.2 mL phosphate-buffered saline
(PBS) every 72 h (non-treated controls group) and (2) mice treated with a combination of monoclonal
antibodies (treated lung cancer group) that included anti-PD1 (RMP1-14; Cat. #BE0146, BioXCell,
West Lebanon, NH, USA), anti-CTLA-4 (9D9; Cat. #BE0164, BioXCell), anti-CD137 (LOB12.3; Cat.
#BE0169, BioXCell), and anti-CD19 (1D3; Cat. #BE0150, BioXCell) antibodies [18,19,21,23–26] (Table 1).
A dose of 5 × 10−3 mg/kg/72 h in 0.2 mL PBS was administered to the treated group of lung cancer mice
from day 15 (tumors visible) up until day 30 (Figure 1). The intraperitoneal route was chosen in order
to mimic administration of this type of therapies in clinical settings [19]. For ethical reasons we were
not allowed to extend the study protocol longer than 30 days. Also for ethical reasons, only non-treated
tumor-bearing mice administered with the vehicle PBS were used as the control group in the study.
Food and water were supplied ad libitum and mice were kept under pathogen-free conditions with
a 12:12 h light:dark cycle in the animal facilities placed in the Barcelona Biomedical Research Park
(PRBB) premises.
2.1.2. In Vivo Measurements Conducted on the Animals
Food intake and body weight were measured daily in all the study animals. Tumor area was also
measured daily using a specific caliper in all the animals.
2.1.3. Sacrifice and Sample Collection
The two experimental groups of mice were sacrificed after 30 days of inoculation of LP07 cells.
In each mouse, an intraperitoneal injection of 0.1 mL sodium pentobarbital (60 mg/kg) was inoculated
prior to sacrifice. In order to verify total anesthesia depth, the pedal and blink reflexes were assessed
in all animals. As the histological features of the subcutaneous tumor and those of the lung metastases
are identical in this LP07 mouse model of lung cancer, for practical reasons, the subcutaneous tumor
was used for the laboratory experiments. As such, the subcutaneous tumor was extracted from all the
mice. A fragment of the tumor specimens was immediately frozen in liquid nitrogen and stored at
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−80 ◦C, while the other fragment was immersed in an alcohol-formol to be thereafter embedded in
paraffin until further use.Cancers 2019, 11, x 4 of 16 
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2.2. Molecular Biology Analyses
2.2.1. Histological Analyses of Tumor Samples
Immunohistochemical techniques were applied on tumor sections in order to explore expression of
the proliferation marker Ki-67 and T cells, following previous methodologies [8,12,13,16,33,36–38,42,43].
Briefly, for all the target antigens, tumor cross-sections were deparaffinized and then antigen retrieval
was carried ut by h ating slides in a water ba in Tris/Ethylenediaminetetraac tic acid (EDTA) buffer,
pH 9, for 30 min (Ki-67 and CD3) or in a pressure-cooker (CD4, CD8) in 0.1 M citrate buffer, pH 6, for
15 min. Subsequently, samples were blocked with 3% H2O2 for 15 min, and immediately afterwards
they were blocked with 1% BSA and goat serum for two hours. Slides were then incubated at room
temperature for 30 min (CD3) or at 4 ◦C overnight (Ki-67, CD4, CD8) with the following specific primary
antibodies: anti-Ki67 (Merck-Millipore, Darmstadt, Germany), anti-CD3 (DAKO, Glostrup, Denmark),
anti-CD4 (Abcam, Cambridge, UK), and anti-CD8 (Abcam). Slides were washed and incubated for
30 min with biotinylated u iversal secondary antibody, followed by another 30 min incubation with
horseradish-conjugated streptavidin and diaminobenzidine for five minutes (kit LSAB+HRP Dako
Cytomation Inc., Carpinteria, CA, USA) as a substrate.
Tumor sections were counterstained ith hematoxylin for two mi utes and were then dehydrated
and mounted for conventional microscopy. Images of the stained tumors were taken under a light
microscope (Olympus BX 61, Olympus Corporation, Tokyo, Japan) coupled with a camera (Olympus
DP 71, Olympus Corporation). The number of Ki-67, CD3, and CD8 cells was expressed as the
percentage of the cells that were positively stained for the corresponding markers of the total cells in
the tumor preparations. The numb r of CD4 cells was represented as the number of cells that were
positively stained for CD4 in the measured area (expressed in micrometers).
Terminal deoxynucleotidyl transferase- mediated uridine 5′-triphosphate (UTP) nick- end labelling (TUNEL)
assay. In tumor paraffin-embedded sections, apoptotic nuclei were identified using the TUNEL assay
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(In Situ Cell Death Detection Kit, POD, Roche Applied Science, Mannheim, Germany) for all study
groups following the manufacturer’s instructions and previous studies [38,43]. Briefly, this assay is
based on the principle that during the apoptosis of nuclei, genomic DNA may yield double-stranded,
low molecular weight fragments as well as single-strand breaks (nicks) in high molecular weight DNA.
These DNA strand breaks can be identified by labelling 3′-hydroxyl (3′OH) groups with modified
nucleotides in an enzymatic reaction. In this assay, deoxynucleotidyl transferase (TdT), which catalyzes
the polymerization of nucleotides to free 3′-OH DNA ends, is used to label DNA strand breaks. Briefly,
diaphragm and gastrocnemius muscle sections were fixed and permeabilized. Subsequently, they were
incubated with the TUNEL reaction mixture that contains terminal TdT and fluorescein-dUTP. During
the incubation period, terminal TdT catalyzed the addition of fluorescein-dUTP at free 3′-OH groups
in single- and double-stranded DNA. After washing, the label incorporated at the damaged sites of
the DNA was marked by anti-fluorescein antibody conjugated with the reporter enzyme peroxidase.
After several washes that removed unbound enzyme conjugate, the peroxidase retained in the immune
complex was visualized by a substrate reaction. Apoptotic nuclei were brown, while negative nuclei
were blue (hematoxylin counterstaining). In each tumor cross-section, the TUNEL-positive nuclei and
the total number of nuclei were counted blindly by two independent observers, who were previously
trained for that purpose. Results were expressed as the ratio of total TUNEL positively-stained nuclei
to the total number of counted nuclei, as also previously reported [38,43]. A minimum amount of
300 nuclei were counted in each tumor preparation. Final results corresponded to the mean value
of the counts provided by the two independent observers (concordance rate 95%). Negative control
experiments, in which the TUNEL reaction mixture was omitted, were also conducted. Moreover, rat
testicles were used as a positive control in these experiments.
2.2.2. Immunoblotting
Protein levels of the target markers were determined using 1D electrophoresis and immunoblotting
according to previously published methodologies [8,12,13,16,33,36–38,42]. Frozen tumor samples
extracted from mice were homogenized in lysis buffer. The following specific primary antibodies
were used to identify the different target markers: protein tyrosine nitration (anti-3-nitrotyrosine
antibody, Invitrogen, Eugene, OR, USA), malondialdehyde protein adducts (anti-MDA protein adduct
antibody, Academic Bio-Medical Company, Inc., Houston, TX, USA), catalase (anti-catalase antibody,
Calbiochem, Darmstadt, Germany), Mn-superoxide dismutase (SOD2, anti-SOD2 antibody, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), CuZn-superoxide dismutase (SOD1, anti-SOD1 antibody,
Santa Cruz), b-cell lymphoma 2 (BCL-2, anti-BCL-2, antibody Santa Cruz), BCL-2 associated X protein
(BAX, anti-BAX antibody, Santa Cruz), nucleoporin p62 (anti-p62 antibody, Sigma-Aldrich, St. Louis,
MO, USA), beclin-1 (anti-beclin-1 antibody, Santa Cruz), microtubule-associated protein 1 light-chain
3 (LC3B, anti-LC3B antibody, Cell Signaling, MA, USA), nuclear factor kappa-light-chain-enhancer
of activated B cells (NF-κB) p65 subunit and phosphorylated p65 subunit (anti NF-κB p65 and
p-NF-κB p65 antibodies, Santa Cruz), sirtuin-1 (anti-sirtuin-1 antibody, EMD Millipore, Billerica,
MA, USA), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, anti-GAPDH antibody, Santa
Cruz) as the protein loading control to confirm identical protein loading among different lanes.
Horseradish peroxidase (HRP)-conjugated secondary antibodies and a chemiluminescence kit (Thermo
Scientific, Rockford, IL, USA) were used to detect the antigens from all samples. For the sake of
comparisons between the two groups, all study samples (×18) were run together in the same mini-cell
electrophoresis and transfer boxes, respectively, and the corresponding membranes were detected
using chemiluminescence in the same platform under identical exposure times.
Polyvinylidene difluoride (PVDF) membranes were scanned with the Molecular Imager Chemidoc
XRS System (Bio-Rad Laboratories, Hercules, CA, USA) using the software Quantity One version 4.6.5
(Bio-Rad Laboratories), and optical densities of target proteins were quantified using the software
Image Lab version 2.0.1 (Bio-Rad Laboratories). Final optical densities (arbitrary units) acquired in
each group of mice corresponded to the average value of all the samples (lanes). Values of optical
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densities (arbitrary units) of LC3B-II/LC3B-I were also calculated as the ratio of LC3B-II (14 kDa) to
LC3B-I (16 kDa) protein content. Moreover, all values of the different antigens were calculated as the
ratio of the optical densities of the given variable to those of the loading control GAPDH in each study
sample, as shown in each figure.
Standard stripping methodologies were employed to detect p62 protein levels in the same PVDF
membranes of beclin-1. The loading control GAPDH was also detected using stripping methodologies
in the study markers: protein tyrosine nitration, MDA-protein adducts, SOD1, SOD2, catalase, BAX,
BCL-2, beclin-1, p62, LC3B, NF-κB p65, pNF-κB p65, and Sirtuin-1. Briefly, primary and secondary
antibodies were stripped off proteins using a stripping solution (25 nM glycine, pH 2.0, and 1% Sodium
Dodecyl Sulphate (SDS)) for 30 min. Membranes were subsequently washed two consecutive times
(10 min each) with phosphate buffered saline and tween (PBST) at room temperature. Immediately
afterwards, membranes were blocked with 1% Bovine Serum Albumin (BSA) and incubated with
specific primary and secondary antibodies following the abovementioned procedures.
2.3. Statistical Analysis
Using specific software (StudySize 2.0, CreoStat HB, Frolunda, Sweden) and assuming an alpha
error of 0.05 and a minimum of 80% of standard power statistics, the sample size (N = 9/group) was
sufficiently great to identify a difference of 700 and 0.6 points in both tumor area and weight variables
between groups, respectively. The Shapiro–Wilk test was used to check the normality of the study
variables. Therefore, data are expressed as mean and standard deviation in both tables and figures.
The Statistical Package for the Social Sciences (SPSS, version 22, SPSS Inc., Chicago, IL, USA) was used
to compare the study variables between the two study groups using the unpaired Student’s t-test, and
statistical significance was established at p ≤ 0.05.
3. Results
3.1. Monoclonal Antibodies Improved Tumor Burden and Body Weight in Mice
As illustrated in Table 2 and Figure 2A, by the end day (30) of the study protocol, in the lung cancer
mice compared to non-treated control mice, treatment with the cocktail of monoclonal antibodies
had significantly improved the following variables: final body weight, body weight gain with and
without tumor, tumor weight (34% reduction), and tumor area (64% reduction). Importantly, levels of
Ki-67-positive nuclei were significantly lower (27% reduction), while TUNEL-positively stained nuclei
were significantly higher (127% increase) in the tumors of mice treated with the monoclonal antibodies
compared to those detected in the non-treated control animals (Figure 2B,C).
Table 2. Physiological and tumor characteristics in the study groups of mice.
Variables Lung Cancer Mice Lung Cancer +Monoclonal Antibodies Mice
Initial body weight (g) 20.41 (1.22) 20.34 (0.79)
Final body weight (g) 19.35 (2.25) 21.39 (1.57), *
Body weight gain (%) −4.27 (10.47) +5.16 (6.33), *
Body weight gain without tumor (%) −15.06 (11.28) −2.66 (8.35), *
Tumor weight (g) 2.38 (0.75) 1.57 (0.89), *
Variables are presented as mean (standard deviation). Statistical significance: * p ≤ 0.05 between the two study
groups of mice.
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control lung cancer group of mice (black color) and lung cancer mice treated with monoclonal 
antibodies group (red color) during the study protocol. (B) Representative histological sections (40×) 
and mean values and standard deviation of Ki-67 in the subcutaneous tumors of the non-treated 
control mice and the treated lung cancer animals. Black arrowheads point towards Ki-67-positively 
stained nuclei (brown color), while red arrowheads point towards Ki-67 negatively stained nuclei 
(purple color). (C) Representative histological sections (40×) and mean values and standard deviation 
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p ≤ 0.05 and ***: p ≤ 0.001 between lung cancer mice compared to the lung cancer-monoclonal 
antibodies group. 
3.2. Immune Microenvironment in Response to the Immunomodulators 
Figure 2. (A) Mean values and standard deviation of subcutaneous tumor area (mm2) of non-treated
control lung cancer group of mice (black color) and lung cancer mice treated with monoclonal antibodies
group (red color) during the study protocol. (B) Representative histological sections (40×) and mean
values and standard deviation of Ki-67 in the subcutaneous tumors of the non-treated control mice
and the treated lung cancer animals. Black arrowheads point towards Ki-67-positively stained nuclei
(brown color), while red arrowheads point towards Ki-67 negatively stained nuclei (purple color).
(C) Representative histological sections (40×) and mean values and standard deviation of TUNEL in
the subcut neous tumors of the non-treated control mice and the treated lung cancer animals. Black
arrowheads point towards TUNEL-positively stained nuclei (brown color), while red arrowheads
point towards TUNEL-negatively stained nuclei (purple color). Statistical significance: *: p ≤ 0.05 and
***: p ≤ 0.001 between lung cancer mice compared to the lung cancer-monoclonal antibodies group.
3.2. Immune Microenvironment in Response to the Immunomodulators
In tumors of mice treated with the monoclonal antibodies, the number of T cells (CD3, CD8, and
CD4) was significantly greater than that observed in the non-treated animals (Table 3 and Figure 3).
Table 3. Immune microenvironment in the study groups of mice.
T Cells Lung Cancer Mice Lung Cancer +Monoclonal Antibodies Mice
CD3 + cells (%) 8.34 (0.91) 11.30 (0.78), ***
CD4 + (cells/µm2) 1.99 × 10−6 (0.44 × 10−6) 3.37 × 10−6 (1.49 × 10−6), *
CD8 + cells (%) 5.16 (1.35) 7.86 (1.04), ***
Values are expressed as mean (standard deviation). Statistical significance: * p ≤ 0.05 and *** p ≤ 0.001 between the
two experimental groups of mice.
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total MDA protein adduct levels/GAPDH in subcutaneous tumors of lung cancer mice as measured
by optical densities. Representative GAPDH is shown as the loading control. Statistical significance
is represented as follows: **: p ≤ 0.01 between non-treated controls (N = 9) in white bars and treated
lung cancer (N = 9) mice in black bars. Definition of abbreviations: MDA, malondialdehyde; GAPDH,
glyceraldehyde-3-phospate dehydrogenase; OD, optical densities.
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Figure 5. (A) Representative immunoblots and mean values and standard deviation of SOD1
protein levels/GAPDH in subcutaneous tumors of lung cancer mice as measured by optical
densities. (B) Representative immunoblots and mean values and standard deviation of SOD2 protein
levels/GAPDH in subcutaneous tumors of lung cancer (LC) mice as measured by optical densities.
(C) Mean values and standard deviation of catalase protein levels/GAPDH in subcutaneous tumors of
lung cancer mice as measured by optical densities. Representative GAPDH is shown as the loading
control. Statistical significance is represented as follows: *: p ≤ 0.05 between non-treated controls (N = 9)
in white bars and treated lung cancer (N = 9) mice in black bars. Definition of abbreviations: SOD1,
CuZn-superoxide dismutase; SOD2, Mn-superoxid dismutase; GAPDH, glyceraldehyde-3-phospate
dehydrogenase; OD, optical densities.
3.4. Tumor Apoptosis and Autophagy Markers in Response to Immunomodulators
Treatment of the mice with the cocktail of m ocl nal antibodies induced a significant rise in
BAX protein levels in the tumors compared to non-treated animals, while no significant differences
were found in tumor BCL-2 protein levels between the two study groups (Figure 6A,B). Treatment
with monoclonal antibodies did not induce any significant difference in protein expression levels of
either beclin-1 or p62, whereas the ratio of LC3-II to LC3-I was significantly increased in the tumors of
the treated mice (Figure 7A–C).
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3.5. Effects of the Immunomodulators on Signaling Markers in Tumors
Protein levels of the ratio of p-p65 subunit to total p65 of the NF-κB signaling pathway were
significantly greater in the tumors of the mice treated with the monoclonal antibodies than in those of
non-treated rodents (Figure 8A). Protein levels of the deacetylase sirtuin-1 were significantly increased
in the tumors of the treated mice compared to non-treated animals (Figure 8B).
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4. Discussion
In the present study, treatment of the tu or-bearing mice with a cocktail of monoclonal antibodies
that specifically targeted immune checkpoints and pa ways elicited a sig ificant reducti n of tumor
proliferatio rates and sizes through the induction of several biological m chanisms that are discussed
below. Thus, the study hypothesis has been confirmed to a great extent.
In the tumors of the mice treated with the cocktail of monoclonal antibodies, the area was
significantly reduced at the end of the study period. These are relevant findings that confirm the
efficacy of the treatment with the immunomodulators of the tumor cells in this experimental model
of lung cancer in mice. These results are in line with those previously reported, in which a complete
regression of the tumors (melanoma and lung cancer) was attained following intratumoral treatment
of the mice with the same cocktail of monoclonal antibodies [18,19]. In the present study, the numbers
of T cell subtypes also s gnificantly increased in the tumors of the mice that received treatment with
the checkpoint inhibitors.
As opposed to previous investigations [18,19], the immunomodulators were injected
intraperitoneally with the aim to mimic the treatments applied in patients, in whom drugs are
usually administered systemically. In this investigation, a complete regression of the tumors was
not achieved, probably as a result of the systemic administration of the drugs compared to previous
reports [18,19], in which the monoclonal antibodies were administered locally. Nonetheless, in the
tumor-bearing mice that received the medical treatment with the immunomodulators a substantial
reduction in tumor burden as measured by both tumor weight (34%) and area (64%) was observed.
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This leads to the conclusion that the treatment, the doses, and the route were effectively administered
in the current study.
Interestingly, the number of tumor proliferating cells was also significantly lower in the tumors
of the mice treated with the monoclonal antibodies than in the non-treated tumor-bearing rodents.
These results suggest that cell cycle arrest probably due to alterations in cyclin expression levels may
account for the reduced levels of Ki-67-positively stained nuclei encountered in the adenocarcinoma
cells of the treated tumor-bearing mice. Moreover, these findings are also in agreement with previous
investigations, in which expression levels of Ki-67 were significantly reduced (34%) in the tumors of
mice treated with several selective inhibitors of cell survival pathways [12], in those from transgenic
mice deficient for either poly(Adenosine Diphosphate Ribose (ADP)-ribose)) polymerases (PARP)-1 or
-2 enzymes [33], and in those of rodents treated with pharmacological inhibitors of PARP activity [44].
Taken together, these results are also very consistent with the findings reported herein: reduced tumor
area and weight in the tumor-bearing mice treated with the immunomodulators at the end of the
study period.
Oxidative stress was assessed using several indirect markers in the tumor cells of both groups of
mice. Importantly, levels of protein tyrosine nitration and total MDA-protein adducts were significantly
greater in the tumor cells of the mice that received treatment with the monoclonal antibodies. These
results are in agreement with those previously observed in another investigation, in which protein
oxidation levels were also increased in the tumors of Parp-1-/- and Parp-2-/- mice [33]. In the present
investigation, levels of the antioxidant enzyme SOD1, but not those of SOD2 or catalase, were
significantly greater in the tumors of the lung cancer-bearing mice treated with the monoclonal
antibodies. These results are in line with those encountered in the tumors of mice treated with the
proteasome inhibitor bortezomib [12]. Furthermore, accumulation of reactive oxygen species (ROS)
and glutathione depletion were also shown in tumor cells of mice with colorectal cancer [34], and an
oxidative stress-associated mechanism of T cell activation was observed in the stroma of ovarian and
colon tumor samples in patients as well [35,45,46].
The rise in the expression of cytosolic SOD1 levels may have been a response to counterbalance
the deleterious effects of increased oxidative stress in the tumor cells as previously suggested [12].
Altogether, a rise in several oxidative stress markers was observed in the tumors of the mice treated with
the cocktail of monoclonal antibodies. These findings may imply that in response to treatment with the
immunomodulators, oxidative stress may drive cell cycle arrest and tumor cell death independently of
the immune response [47].
Oxidative stress may also trigger several important cellular pathways such as cell death, apoptosis,
and autophagy through signaling pathways such as the redox sensitive NF-κB pathway. In this regard,
the ratio levels of active p65 (phosphorylated) to total p65 were greater in the tumors of animals treated
with the monoclonal antibodies than in the non-treated mice. Importantly, levels of TUNEL-positive
nuclei were also significantly increased in tumors of the mice treated with the immunomodulators.
Additionally, Bax protein levels also increased in the tumors of mice treated with the monoclonal
antibodies, while no differences in Bcl2 levels were seen between the study groups. These results
are consistent with those previously reported, in which different therapeutic strategies also elicited
a rise in proapoptotic markers [12,33]. The increase in apoptotic markers of cancer cells was also
demonstrated in previous investigations in which the animals were treated with selective inhibitors of
PARP activity [44,48–50].
A rise in the autophagy marker LC3B was observed in the tumor cells of the mice treated with the
immunomodulators compared to non-treated control rodents. These results imply that autophagy
may also mediate the reduced tumor burden observed in the mice that received treatment with the
cocktail of monoclonal antibodies. In fact, similar results were previously demonstrated in the tumors
of mice that were genetically deficient for either PARP-1 or PARP-2 proteins, especially the latter [33].
The deacetylase sirtuin-1 may play a role in autophagy as a result of its upstream regulation of
LC3B [51]. In the current study, a significant rise in protein levels of sirtuin-1 was detected in the
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tumor cells of the mice treated with the monoclonal antibodies compared to non-treated animals.
On the other hand, sirtuin-1 may also play a role in the regulation of tumor microenvironment of
the immune cells [52]. These results imply that sirtuin-1 probably interfered with immune cells [52],
leading to changes in the tumor microenvironment (from Th2 type to Th1 immunity) as previously
demonstrated [18,19]. This may further contribute to the reduced tumor burden observed in the mice
treated with the monoclonal antibodies. Despite the relevance of this question, it will have to be fully
elucidated in future investigations as it was clearly beyond the objectives of the current investigation.
Study Limitations
Limitations inherent to the use of an animal experimental model may have occurred in the current
investigation as compared to clinical studies. This may partly preclude the generalization of the
present study results to clinical settings. Moreover, other limitations may be related to the type of
tumor cells and the animal background as well as the type of laboratory techniques employed to
identify the different immune cells compared to previous investigations [18,19]. Procedures beyond the
histology, such as flow cytometry, may be useful to selectively identify the type and number of the cells
contained in the tumors. Nonetheless, these experiments would have required a completely different
experimental approach at the time of conducting the animal experiments and when collecting the
tumor specimens. On the other hand, the histological approach enabled us to identify topographically
the presence of the T cells within the cancer specimens, thus confirming that they were, indeed, part of
the tumor microenvironment.
Another possible limitation in the study would be related to the lack of additional control groups
of mice, such as animals administered with isotype-matched antibodies to confirm the selectivity and
specificity of the immunotherapy. Nevertheless, as the efficacy and selectivity of the antibodies used in
the present investigation had already been demonstrated in previous studies [18,19] and for ethical
reasons, no additional control groups were included. Despite all these limitations, the experiments
reported herein shed light onto novel mechanisms whereby immunotherapy may exert beneficial
effects in lung adenocarcinoma tumors.
5. Conclusions
We have demonstrated that immunomodulators with different mechanisms of action elicited
a reduction in the tumor burden as measured by tumor size and weight through several biological
mechanisms, namely decreased tumor proliferation rates and increased T cell counts, oxidative stress,
apoptosis, autophagy, and signaling pathways, which may have interfered with the immune profile
of the tumor microenvironment. Future research should be devoted to the elucidation of the specific
contribution of each mechanism (reduced tumor proliferation, increased tumor degradation, and
stimulation of the immune tumor microenvironment) to the reduced tumor burden seen in this animal
model of lung cancer. These findings may have potential therapeutic implications in patients under
treatment with immunomodulators for their lung neoplasms.
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